Morgan Stanley decreased its holdings in shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) by 12.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 278,072 shares of the company’s stock after selling 40,128 shares during the period. Morgan Stanley owned 0.09% of Amneal Pharmaceuticals worth $6,171,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in AMRX. JPMorgan Chase & Co. increased its position in shares of Amneal Pharmaceuticals by 12.8% during the third quarter. JPMorgan Chase & Co. now owns 24,155 shares of the company’s stock valued at $536,000 after acquiring an additional 2,739 shares in the last quarter. Icon Advisers Inc. Co. boosted its holdings in Amneal Pharmaceuticals by 11.3% in the third quarter. Icon Advisers Inc. Co. now owns 32,500 shares of the company’s stock worth $721,000 after purchasing an additional 3,300 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in Amneal Pharmaceuticals by 14.9% in the third quarter. Hsbc Holdings PLC now owns 28,613 shares of the company’s stock worth $635,000 after purchasing an additional 3,706 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in Amneal Pharmaceuticals in the third quarter worth approximately $101,000. Finally, Great West Life Assurance Co. Can boosted its holdings in Amneal Pharmaceuticals by 63.4% in the third quarter. Great West Life Assurance Co. Can now owns 12,969 shares of the company’s stock worth $288,000 after purchasing an additional 5,033 shares during the last quarter. 35.56% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE AMRX opened at $13.47 on Thursday. The company has a debt-to-equity ratio of 2.92, a quick ratio of 1.26 and a current ratio of 1.91. The firm has a market capitalization of $4.18 billion, a price-to-earnings ratio of 22.24, a P/E/G ratio of 0.52 and a beta of 1.38. Amneal Pharmaceuticals Inc has a 52-week low of $11.66 and a 52-week high of $24.48.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, January 14th. Leerink Swann restated an “outperform” rating and issued a $19.00 target price (down previously from $25.00) on shares of Amneal Pharmaceuticals in a report on Thursday, January 3rd. Morgan Stanley cut shares of Amneal Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $24.00 to $18.00 in a report on Friday, December 14th. Finally, ValuEngine cut shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 10th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $21.67.
ILLEGAL ACTIVITY WARNING: “Morgan Stanley Has $6.17 Million Holdings in Amneal Pharmaceuticals Inc (AMRX)” was published by Macon Daily and is the sole property of of Macon Daily. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://macondaily.com/2019/02/21/morgan-stanley-has-6-17-million-holdings-in-amneal-pharmaceuticals-inc-amrx.html.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Read More: What are earnings reports?
Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals Inc (NYSE:AMRX).
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.